PLK4 as a potential target to enhance radiosensitivity in triple-negative breast cancer

Abstract Radioresistance is one of the barriers to developing more effective therapies against the most aggressive, triple-negative, breast cancer (TNBC) subtype. In our previous studies, we showed that inhibition of Polo-like Kinase 4 (PLK4) by a novel drug, CFI-400945 significantly enhances the an...

Full description

Bibliographic Details
Published in:Radiation Oncology
Main Authors: Sierra Pellizzari, Vasudeva Bhat, Harjot Athwal, David W. Cescon, Alison L. Allan, Armen Parsyan
Format: Article
Language:English
Published: BMC 2024-02-01
Subjects:
Breast Cancer
Centrinone B
CFI-400945
Combination therapy
Radiotherapy
Organoids
Online Access:https://doi.org/10.1186/s13014-024-02410-z

Internet

https://doi.org/10.1186/s13014-024-02410-z

Similar Items